Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient

Clinical Transplantation

Volumn 11, Issue 6, 1997, Pages 608-612

  Kfoury, Abdallah G ^a   Smith, Julie C ^a   Farhoud, Hussam H ^a   Terreros, Daniel A ^a   Stringham, James C ^a   Taylor, David O ^a   Renlund, Dale G ^a  

^a NONE

Author keywords

Amphotericin B; Heart transplantation; Mucormycosis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT;

ADULT; ARTICLE; CASE REPORT; HEART TRANSPLANTATION; HUMAN; INFECTIOUS COMPLICATION; INTRAPLEURAL DRUG ADMINISTRATION; LUNG INFECTION; MALE; MUCORMYCOSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RHIZOPUS;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; HEART TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRALESIONAL; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; MUCORMYCOSIS; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030694857     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. GENTRY LU, ZELUFF BJ. Diagnosis and treatment of infections in cardiac transplant patients. Surg Clin North Am 1986: 6: 459.
2. HOFFIN JM, POTASMAN I, BALDWIN JC, OYER PE, STINSON EB, REMINGTON. JS. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987: 106: 209.
3. DUMMEN JS, HARDY A, POORSATTER A, HO M. Early infection in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983: 36: 259.
4. HART PD, RUSSEL, E, REMINGTON JS. The compromised host and infection. J Infect Dis 1969: 120: 169.
5. MILLER L. Long-term complication of cardiac transplantation. Prog Cardiovasc Dis 1991: 4: 229.
6. ANDREONE PA, OLIVARI MT, ELICK B, et al. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J Heart Transpl 1986: 5: 13.
7. DRESDALE A, DIEHL J. Early postoperative care: Infectious consideration. Prog Cardiovasc Dis 1990: 33: 1.
8. MEYERS BR, WORMSER G, HIRSCHMAN SZ, et al. Rhinocerebral mucormycosis, diagnosis and therapy. Arch Intern Med 1979: 139: 57.
9. BLITZER A, LAWWSON W, MEYERS BR, et al. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 1980: 90: 635.
10. PARFREY NA. Improved diagnosis and prognosis of mucormycosis. Medicine 1986: 65: 113.
11. LEHRER R. Mucormycosis. Ann Intern Med 1980: 93: 93.
12. MEYER RD, ROSEN P, ARMSTRONG D. Phycomycosis complicating leukemia and lymphoma. Ann Intern Med 1972: 77: 871.
13. MARCHEVSKY AM, BOTTONE EJ, GELLER SA, et al. The changing spectrum of disease etiology and diagnosis of mucormycosis. Hum Pathol 1980: 11: 457.
14. BOELAERT JR, FENVES AZ, COBURN JW. Deferoxamine therapy and mucormycosis m dialysis patients: report of an international registry. Am J Kidney Dis 1991: 6: 660.
15. KERK CM, PERFECT JR, CRAVEN PC, et al. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis Ann Intern Med 1983: 99: 334.
16. RUBIN J, ROGERS WA, TAYLOR HM, et al. Peritonitis during continuous ambulatory peritoneal dialysis. Ann Intern Med 1980: 92: 7.
17. BAYER AS, BLUMENKRARTZ MJ, MONTGOMERIE JZ, GALPIN JE, COBURN JW, GUZE LB. Candida peritonitis. Report of 22 cases and review of the English literature. Am J Med 1976: 61: 832.
18. BOELAERT JR, VANCUTSEM J, DELOCHT M, SCHNEIDER YJ, CRICHTON RR. Deferoxamine augments growth and pathogenicity of Rhizopus, and hydroxypyridirione chelators have no effect. Kidney Int 1994: 45: 667.
19. BOELAERT JR, DELOCHT M, SCHNEIDER YJ. The effect of deferoxamine on different zygomycetes. J Infect Dis 1994: 169: 231.
20. EISENBERG L, WOOD T, BOLES R. Mucormycosis. Laryngoscope 1977: 87: 347.
21. YANAGISAWA E, FRIEDMAN S, KUNDARGI RS, SMITH HW. Rhinocerebral phycomycocis Laryngoscope 1977: 87: 1319.
22. PILLSBURY H, FISCHER ND. Rhinocerebral mucormycosis. Aren Otolaryngol Head Neck Surg 1977: 103: 600.
23. POLLOCK RA, PRATT RC, SHULMAN JA, TURNER JS. Nasal mucormycosis: Early detection and treatment without radical surgery or amphotericin B. South Med J 1979: 68: 1279.
24. SANDLER R, TALLMAN CB, KEAMY DG, IRVING WR. Successfully treated rhinocerebral phycomycosis in well controlled diabetes. N Engl J Med 1971: 285: 1180.
25. SAROSI GA, DAVIES SF. Therapy for fungal infections. Mayo Clin Proc 1994: 69: 1111.
26. DAVIES SF. Fungal pneumonia. Med Clin North Am 1994: 5: 1049.
27. LYMAN CA, WALSH TL. Systemically administered anti-fungal agents, a review of their clinical pharmacology and therapeutic applications. Drugs 1992: 44: 9.
28. SAWAYA BP, BRIGGS JP, SCHNERMANN J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J Am Soc Nephrol 1995: 6: 154.
29. JANKNEGT R, DEMARIE S, BAKKER-WOUDENBERG I, CROMMELIN DJA. Liposomal and lipid formulations of amphotericin B, clinical pharmacokinetics. Clin Pharmacokinet 1992: 23: 279.
30. ANDERSON RP, CLARK DA. Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacotherapy 1995: 29: 496.
31. KLINE S, LARSEN TA, FIEBER L, et al. Limited toxicity of prolonged therapy with high doses of amphotericin B Clin Infect Dis 1995: 21: 1154.
32. MEUNIER F, PRENTICE HG, RINGDEN O. Liposomal amphotericin B (AmBisome): Safety from a phase II/III clinical trial. J Antimicrobial Chemotherapy 1991: 28: 83.
33. MUNCKHOF W, JONES R, TOSOLINI FA, MARZEC A, ANGUS P, GRAYSON ML. Cure of Rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin B. Clin Infect Dis 1993: 16: 183.
34. MANNER GPM, VAN DER BIJ W, DE BOER W. Liposomal amphotericin B in three lung transplant recipients. J Heart Lung Transpl 1995: 14: 781.
35. ERICSSON M, ANNIKO M, GUSTAFSSON H, HJALT CA, STENLING R, TARNVIK A. A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Clin Infect Dis 1993: 16: 585.
36. VAS SL. Infections of continuous ambulatory peritoneal dialysis catheters. Infect Dis Clin North Am 1989: 3: 301.
37. EISENBERG ES, LEVITRON I, SOEIRO R. Fungal peritonitis m patients receiving peritoneal dialysis: Experience with 11 patients and review of the literature. Rev Infect Dis 1986: 8: 309.
38. COCHRANE LJ, MORANO JU, NORMAN JR, MANSEL JK. Use of intracavitary amphotericin B in a patient with aspergilloma and recurrent hemoptysis. Am J Med 1991: 90: 654.
39. SHAPIRO MJ, ALBELDA SM, MAYOCK RL, MCLEAN GK. Severe hemoptysis associated with pulmonary aspergilloma: percutaneous intracavitary treatment. Chest 1988: 94: 1225.
40. RAMIREZ RJ. Pulmonary aspergilloma: endobronchial treatment. N Engl J Med 1964: 271: 1281.
41. CHRISTIANSEN KJ, BERNARD EM, GOLD JWM, et al. Distribution and activity of amphotericin B in humans. J Infect Dis 1985: 152: 1307.
42. STUDEMEISTER AE, KOZAK K, GARRITY E, VENEZIO FR. Survival of a heart transplant recipient after pulmonary cavitary mucormycosis. J Heart Transpl 1988: 7: 159.